 IRVINE, CA ACCESSWIRE June 1, 2020 Hancock Jaffe Laboratories, Inc. HJLINASDAQ:HJLIW, a developer of medical devices that restore cardiac and vascular health, announced today it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 1.333 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and one warrant to purchase one share of common stock will be 0.455, which is priced at-the-market under Nasdaq rules. Under the terms of the purchase agreement, HJLI has agreed to sell 2,930,402 shares of its common stock. 